Parry-Jones N, Gore M E, Taylor J, Treleaven J G
Departments of Haematology and Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Clin Lab Haematol. 1999 Dec;21(6):407-8. doi: 10.1046/j.1365-2257.1999.00260.x.
Anti-M is usually a naturally occurring cold-reactive immunoglobulin M (IgM) antibody, often with an immunoglobulin G (IgG) component, and is seldom implicated in delayed haemolytic transfusion reactions (DHTR). However, cases have been reported. In the majority, a DHTR is not suspected until further blood is requested and a new antibody is detected on pretransfusion testing. We describe the case of a young man receiving therapy with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) for metastatic renal cell cancer who developed a clinically suspected DHTR that was confirmed serologically to be caused by anti-M, reactive at 37 degrees C. We discuss the possible role of his biochemotherapy in the development of the DHTR.
抗-M通常是一种天然存在的冷反应性免疫球蛋白M(IgM)抗体,常伴有免疫球蛋白G(IgG)成分,很少引发迟发性溶血性输血反应(DHTR)。然而,已有相关病例报道。大多数情况下,直到再次需要输血并在输血前检测中发现新抗体时,才会怀疑发生了DHTR。我们描述了一名患有转移性肾细胞癌的年轻男子,他正在接受白细胞介素-2(IL-2)和α干扰素(IFN-α)治疗,发生了临床疑似的DHTR,血清学证实是由抗-M引起的,该抗体在37℃时具有反应性。我们讨论了他的生物化疗在DHTR发生过程中可能起到的作用。